Literature DB >> 24319557

Can Sex-hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?

Ferdous Mehrabian1, Maryam Afghahi.   

Abstract

BACKGROUND: This study aims to evaluate the sex hormone binding globulin (SHBG) level as a predictor of response to pharmacological treatment in women with polycystic ovary syndrome (PCOS).
METHODS: This study was conducted in 2009-2012 in Isfahan, Iran. Anovulatory women with a diagnosis of PCOSwere studied. Metformin was started at 500 mg three times a day. If no ovulation occurred, Clomiphene citrate was added.
RESULTS: The study comprised273 infertile women with PCOS completed the study, 75 (28%) of them became pregnant 6 months after treatment (7.36% with metformin and 20.14% with metformin and clomiphene citrate). Patients who responded to metformin treatment had significantly lower mean SHBG levels compared to those who did not (0.88+0.32vs. 0.2642+0.44 nmol/L, respectively, P<0.0001). The area under the ROC curve (AUC) for prediction the response to treatment was 0.85. The baseline level of 27was the most appropriate cut of point HSBG for the prediction of conception. HSBG had a sensitivity of 88%, and specificity of 73.6%. It had a false positive level of 26.4% and false negative level of 12%. Its positive predictive value was 56.4% and its negative predictive value was 94%. The chance of conception increased for reducing a unit of fpg (OR = 0.69; 95% CI = 0.54-0.86; P = .002), as well as reducing of every unit of HSBG (OR = 0.47; 95% CI = 0.39-0.56; P <0.001), and for reducing each unit of insulin in (OR = 0.082; 95% CI = 1.021-0.33; P <0.001).
CONCLUSION: HSBG test is suggested as an appropriate test for predicting pregnancy achievement of PCOs women after pharmacological treatment.

Entities:  

Keywords:  Binding globulin; metformin; polycystic ovary syndrome; sex-hormone

Year:  2013        PMID: 24319557      PMCID: PMC3843304     

Source DB:  PubMed          Journal:  Int J Prev Med        ISSN: 2008-7802


  11 in total

1.  Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

Authors:  P Moghetti; R Castello; C Negri; F Tosi; F Perrone; M Caputo; E Zanolin; M Muggeo
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

2.  Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells.

Authors:  J F Cara; R L Rosenfield
Journal:  Endocrinology       Date:  1988-08       Impact factor: 4.736

3.  The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria.

Authors:  Ferdous Mehrabian; Behnaz Khani; Roya Kelishadi; Elham Ghanbari
Journal:  Endokrynol Pol       Date:  2011       Impact factor: 1.582

4.  Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.

Authors:  Stefano Palomba; Francesco Orio; Angela Falbo; Francesco Manguso; Tiziana Russo; Teresa Cascella; Achille Tolino; Enrico Carmina; Annamaria Colao; Fulvio Zullo
Journal:  J Clin Endocrinol Metab       Date:  2005-04-19       Impact factor: 5.958

Review 5.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

6.  Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome.

Authors:  Müberra Kocak; Eray Caliskan; Coskun Simsir; Ali Haberal
Journal:  Fertil Steril       Date:  2002-01       Impact factor: 7.329

7.  Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease.

Authors:  G A Burghen; J R Givens; A E Kitabchi
Journal:  J Clin Endocrinol Metab       Date:  1980-01       Impact factor: 5.958

8.  Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.

Authors:  J E Nestler; D J Jakubowicz
Journal:  N Engl J Med       Date:  1996-08-29       Impact factor: 91.245

9.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

Authors: 
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

10.  Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin.

Authors:  C Bergh; B Carlsson; J H Olsson; U Selleskog; T Hillensjö
Journal:  Fertil Steril       Date:  1993-02       Impact factor: 7.329

View more
  1 in total

Review 1.  Impact of Increased Oxidative Stress on Cardiovascular Diseases in Women With Polycystic Ovary Syndrome.

Authors:  Florentina Duică; Cezara Alina Dănilă; Andreea Elena Boboc; Panagiotis Antoniadis; Carmen Elena Condrat; Sebastian Onciul; Nicolae Suciu; Sanda Maria Creţoiu; Valentin Nicolae Varlas; Dragoş Creţoiu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-18       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.